organization · Reporting owner
Vida Ventures Management Co. LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LB PHARMACEUTICALS INC
Report date September 12, 2025 · Filed September 16, 2025
Jointly reported with Vida Ventures GP III, L.L.C., Vida Ventures III, L.P., Vida Ventures III-A, L.P., Belldegrun Arie
Section 16 reporting ended · disclosed 2025-09-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures III, L.P. | 880,214 |
Last balance in matching sequence
After 2025-09-12 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-09-12 · Conversion · Acquired 547,648 · Balance 547,648 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Row 3 · 2025-09-12 · Purchase · Acquired 332,566 · Balance 880,214 F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures III-A, L.P. | 2,029 |
Last balance in matching sequence
After 2025-09-12 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2025-09-12 · Conversion · Acquired 1,262 · Balance 1,262 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Row 4 · 2025-09-12 · Purchase · Acquired 767 · Balance 2,029 F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures III, L.P. | 0 |
Reported balance
After 2025-09-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-09-12 · Conversion · Disposed 13,302,666 · Balance 0 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures III-A, L.P. | 0 |
Reported balance
After 2025-09-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-09-12 · Conversion · Disposed 30,667 · Balance 0 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures Management Co. LLC | 1,434 |
Reported balance
Holding disclosure · report date 2025-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,434 F5: These shares are held directly by Vida Ventures Management Co., LLC ("Vida Management"). Each Investment Committee Member (as defined below) disclaims beneficial ownership of the securities held of record by Vida Management, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.
F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").
F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F5: These shares are held directly by Vida Ventures Management Co., LLC ("Vida Management"). Each Investment Committee Member (as defined below) disclaims beneficial ownership of the securities held of record by Vida Management, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | ConversionSeries C Preferred Stock · Derivative | 30,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · derivative · entry 7 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | ConversionSeries C Preferred Stock · Derivative | 13,302,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · derivative · entry 6 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 547,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | PurchaseCommon Stock | 767 | $15.00 | $11,505.00 |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 4 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 2,029 F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | PurchaseCommon Stock | 332,566 | $15.00 | $4,988,490.00 |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 3 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 880,214 F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | ConversionCommon Stock | 1,262 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 2 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 1,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | ConversionCommon Stock | 547,648 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 1 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 547,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.